SFD Stock Analysis: Smithfield Foods, Common | NASDAQ
Packaged Foods | NASDAQ, USA | Market Cap: 7.426m USD | 12M Return: -10.3% | US8322482071 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 39.5M
Qual. Beats: 0
Rev. Trend: 62.4%
Warnings
Tailwinds
No distinct edge detected
Seasonality 1.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Smithfield Foods, Inc. (NASDAQ: SFD) is a vertically integrated producer of packaged meats and fresh pork products, operating across four segments: Packaged Meats, Fresh Pork, Hog Production, and Other. The Packaged Meats segment offers branded and private-label products including bacon, sausage, hot dogs, deli meats, ham, and prepared foods under a portfolio of well-known labels such as Smithfield, Eckrich, Nathans Famous, Farmland, Armour, and John Morrell. The Fresh Pork segment converts live hogs into primal, sub-primal, and offal cuts sold to retail, foodservice, industrial, and export customers in markets such as China, Mexico, Japan, South Korea, and Canada. Hog Production raises hogs on company-owned and contract farms and also sells livestock feed and grains. The Other segment includes bioscience operations that manufacture heparin, an active pharmaceutical ingredient derived from hog byproducts and used as a blood anticoagulant, along with fresh pork production in Mexico. Founded in 1936 and headquartered in Smithfield, Virginia, the company is a subsidiary of SFDS UK Holdings Limited.
Smithfields vertically integrated structure, spanning hog farming through to branded packaged meats, is characteristic of large-scale producers in the U.S. Packaged Foods & Meats sub-industry, which is part of the Consumer Staples sector and tends to be relatively resilient to economic cycles due to steady demand for protein products. Heparin production is a notable specialty byproducts business, as porcine-derived heparin is a globally significant source of this anticoagulant pharmaceutical ingredient.
- Pork export demand from China and Mexico drives Fresh Pork revenue
- Hog feed costs pressure margins across Hog Production segment
- Packaged meats brands face competition from Tyson and Hormel
| Net Income: 1.06b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -0.01 > 1.0 |
| NWC/Revenue: 19.77% < 20% (prev 19.89%; Δ -0.13% < -1%) |
| CFO/TA 0.10 > 3% & CFO 1.16b > Net Income 1.06b |
| Net Debt (1.44b) to EBITDA (1.65b): 0.87 < 3 |
| Current Ratio: 2.56 > 1.5 & < 3 |
| Outstanding Shares: last quarter (395.8m) vs 12m ago 0.51% < -2% |
| Gross Margin: 13.18% > 18% (prev 13.58%; Δ -0.40% > 0.5%) |
| Asset Turnover: 133.1% > 50% (prev 132.7%; Δ 0.42% > 0%) |
| Interest Coverage Ratio: 37.43 > 6 (EBIT TTM 1.31b / Interest Expense TTM 35.0m) |
| A: 0.25 (Total Current Assets 5.01b - Total Current Liabilities 1.95b) / Total Assets 12.0b |
| B: 0.33 (Retained Earnings 4.01b / Total Assets 12.0b) |
| C: 0.11 (EBIT TTM 1.31b / Avg Total Assets 11.6b) |
| D: 1.49 (Book Value of Equity 7.00b / Total Liabilities 4.70b) |
| Altman-Z'' = 5.08 = AAA |
| DSRI: 1.26 (Receivables 1.01b/773.0m, Revenue 15.4b/14.8b) |
| GMI: 1.03 (GM 13.58% / 13.18%) |
| AQI: 0.95 (AQ_t 0.28 / AQ_t-1 0.30) |
| SGI: 1.04 (Revenue 15.4b / 14.8b) |
| TATA: -0.01 (NI 1.06b - CFO 1.16b) / TA 12.0b) |
| Beneish M = -2.79 (Cap -4..+1) = A |
As of October 12, 2026, the stock is trading at USD 18.61 with a total of 1,759,285 shares traded. Over the past week, the price has changed by -1.33%, over one month by -9.31%, over three months by -23.94% and over the past year by -10.33%.
Current recommended Stop Loss: 18.00 (which is 3.3% or 1.4 ATR below the current price).
Smithfield Foods, Common has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy SFD.
- StrongBuy: 4
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 26.1 | 40.1% |
P/E Trailing = 7.0112
P/E Forward = 10.4932
P/S = 0.48
P/B = 1.0651
Revenue TTM = 15.4b USD
EBIT TTM = 1.31b USD
EBITDA TTM = 1.65b USD
Long Term Debt = 1.40b USD (from longTermDebt, last quarter)
Short Term Debt = 675.0m USD (from shortTermDebt, last quarter)
Debt = 2.79b USD (from shortLongTermDebtTotal, last quarter) + Leases 392.0m
Net Debt = 1.44b USD (calculated: Debt 2.79b - CCE 1.35b)
Enterprise Value = 8.86b USD (7.43b + Debt 2.79b - CCE 1.35b)
Interest Coverage Ratio = 37.43 (Ebit TTM 1.31b / Interest Expense TTM 35.0m)
EV/FCF = 11.05x (Enterprise Value 8.86b / FCF TTM 802.0m)
FCF Yield = 9.05% (FCF TTM 802.0m / Enterprise Value 8.86b)
FCF Margin = 5.19% (FCF TTM 802.0m / Revenue TTM 15.4b)
Net Margin = 6.85% (Net Income TTM 1.06b / Revenue TTM 15.4b)
Gross Margin = 13.18% ((Revenue TTM 15.4b - Cost of Revenue TTM 13.4b) / Revenue TTM)
Gross Margin QoQ = 12.08% (prev 13.45%)
Tobins Q-Ratio = 0.74 (Enterprise Value 8.86b / Total Assets 12.0b)
Interest Expense / Debt = 1.26% (Interest Expense 35.0m / Debt 2.79b)
Taxrate = 21.02% (285.0m / 1.36b)
NOPAT = 1.03b (EBIT 1.31b * (1 - 21.02%))
Current Ratio = 2.56 (Total Current Assets 5.01b / Total Current Liabilities 1.95b)
Debt / Equity = 0.40 (Debt 2.79b / totalStockholderEquity, last quarter 7.00b)
Debt / EBITDA = 0.87 (Net Debt 1.44b / EBITDA 1.65b)
Debt / FCF = 1.79 (Net Debt 1.44b / FCF TTM 802.0m)
Total Stockholder Equity = 6.78b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.12% (Net Income 1.06b / Total Assets 12.0b)
RoE = 15.60% (Net Income TTM 1.06b / Total Stockholder Equity 6.78b)
RoCE = 16.00% (EBIT 1.31b / Capital Employed (Equity 6.78b + L.T.Debt 1.40b))
RoIC = 10.39% (NOPAT 1.03b / Invested Capital 9.96b)
WACC = 4.29% (E(7.43b)/V(10.2b) * Re(5.53%) + D(2.79b)/V(10.2b) * Rd(1.26%) * (1-Tc(0.21)))
Discount Rate = 5.53% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 87.00 | Cagr: 0.30%
[DCF] Terminal Value 76.34% ; FCFF base≈780.4m ; Y1≈830.5m ; Y5≈988.1m
[DCF] Fair Price = 34.92 (EV 15.2b - Net Debt 1.44b = Equity 13.7b / Shares 393.8m; r=8.35% [WACC [floored]]; 5y FCF grow 7.22% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.46 | # QB: 0
Revenue Correlation: 62.36 | Revenue CAGR: 3.00% | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.27 | Chg30d=-42.01% | Revisions=-50% | Analysts=4
EPS current Year (2026-12-31): EPS=2.18 | Chg30d=-13.61% | Revisions=-57% | GrowthEPS=-14.5% | GrowthRev=-0.0%
EPS next Year (2027-12-31): EPS=2.19 | Chg30d=-10.40% | Revisions=-57% | GrowthEPS=+0.6% | GrowthRev=-0.7%
[Analyst] Revisions Ratio: -79% (up=0, down=11)